Attovia Therapeutics
Ming Xu has a diverse and solid background in finance and operations, with experience that includes roles in companies such as Attovia Therapeutics, Zai Lab, AbbVie, Deloitte, and Fukuya Hasegawa Partners, LLC. Their educational background includes a Master of Accountancy from the University of Hawaii at Manoa and a Bachelor of Accounting from Xi'an Jiaotong University. Ming Xu currently holds the position of Director, Finance and Ops at Attovia Therapeutics.
This person is not in any teams
Attovia Therapeutics
Attovia is creating a pipeline of biotherapeutics with an initial focus on immune-mediated disease and oncology. We leverage ATTOBODY, a novel biologics platform, to generate small format biparatopic binders that unlock the spatial aspect of target engagement. The biparatopic binding mode of ATTOBODIES translates to picomolar affinity with glue-like off-rates, exquisite specificity, and accelerated target internalization. Their small format and modularity offer fast tissue penetration, ease of engineering into bispecifics, and tunable half-life from hours to weeks. Collectively, these properties of ATTOBODIES expand the addressable target and epitope universe across disease areas and can offer stronger efficacy, faster speed to response, and an improved safety profile compared to traditional approaches. By utilizing our ATTOBODY technology, we will develop novel medicines that target unaddressed elements of disease, as well as offer better efficacy and tolerability. We envision a world where no patient is left behind.